Premium
Injection of Glutaraldehyde Cross‐Linked Collagen for Urinary Incontinence: Two‐Year Efficacy by Self‐Assessment
Author(s) -
Hornma Yukio,
Kawabe Kazuki,
Kageyama Shinji,
Koiso Kenkichi,
Akaza Hideyuki,
Kakizoe Tadao,
Koshiba Ken,
Yokoyama Eiji,
Aso Yoshio
Publication year - 1996
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1996.tb00496.x
Subject(s) - medicine , urinary incontinence , urology , urine , glutaraldehyde , urinary system , urethral sphincter , stress incontinence , residual urine , sphincter , surgery , pathology , prostate , cancer
Background: Glutaraldehyde cross‐linked (GAX) collagen has recently become available ds injection material for treatment of urinary incontinence and should be evaluated for its long‐term efficacy. Methods: The subjects included 78 females with genuine stress incontinence (GSI) and 19 male or female patients with intrinsic sphincter deficiency (ISD: urinary incontinence due to urethrdl sphincter damage). GAX collagen was injected transperineally or trdnsurethrally through an injection needle under direct endoscopic observation. The efficacy was evaluated by the patients' overall assessment at two years post‐treatment. Results: Under local or regional anesthesia, CAX collagen was injected 1.9 times on average (total injection volume: 23.5 mL) in GSJ patients and 2.2 times (40.1 mL) in ISD patients. Improvement at two years post‐treatment by patients' assessment was observed in 71.7% of GSI patients and 53.3% in ISD patients. Side effects were urinary retention and difficulty in voiding after 48 of the total of 188 injections (15.5%). a large amount of residual urine in four (2.1%) and miscellaneous in 19 (10.1%), for a short period after injection and were not serious. Conclusion: Our study indicates that GAX collagen injection is an effective, safe and easy non‐medical treatment for urinary incontinent patients.